Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FaR-RMS
2024-510579-40-00Phase 2Authorised
- Sponsor
- University of Birmingham
- Start
- Nov 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 23
01
Overview
Phase 2, randomised, open-label trial of regorafenib, irinotecan, vinorelbine, temozolomide, ifosfamide and 4 more in rhabdomyosarcoma (RMS) (8 arms), sponsored by University of Birmingham. Primary endpoints: Recommended Phase 2 Dose, Event-free survival and 1 more. Planned start Nov 2024; status: authorised.
02
Drugs
regorafenibirinotecanvinorelbinetemozolomideifosfamide
03
Conditions
rhabdomyosarcoma (RMS)
Beyond the preview
Go deeper on 2024-510579-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510579-40-00.